Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A Powerful Demonstration: MTM May Be Counterpoint To Pricing Complaints

This article was originally published in RPM Report

Executive Summary

A proposed “enhanced” model for Medication Therapy Management in Medicare Part D draws rave reviews from a House subcommittee. The prospect of using medication better to lower overall costs is a great counterpoint to headlines about excessive drug prices.

You may also be interested in...



Medication Therapy Management: The Gap Between Theory And Practice

US Medicare Payment Advisory Commission still sees promise in ‘Medication Therapy Management’ programs. But why is the value of enhanced pharmacy support for patients on complex prescription regimens so hard to prove in actual practice?

Medicare Part D ‘Enhanced’ MTM Model: Not Much To Show After Three Years?

Medication therapy management program has not produced savings in Medicare spending on medical services or a significant, consistent benefit on improving adherence or reducing hospitalizations, report finds.

Medicare Part D ‘Enhanced MTM Model’ Saves $325m In First Year

US Centers for Medicare and Medicaid Services announces first-year results from its medication therapy management model, intended to optimize prescription drug use among Medicare beneficiaries.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS079783

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel